Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


BioVisioN receives research grant for biomarker discovery

July 29, 2005 -- Developing methods to discover and identify biomarkers is the mission of BioVisioN AG. The German based biotech company uses proprietary technologies for the analysis of pep-tides in biological samples. The aim is to identify putative biomarkers that may support the development of drugs and improve the diagnosis of diseases. The BioProfile 'Functional Genome Analysis' has recommended a project of BioVisioN to be funded by the German Federal Ministry of Education and Research (BMBF) with 500.000 Euro.

Biomarkers are biological characteristics that act as indicators of normal biological processes, dis-ease processes or response to therapeutic intervention. The presence of certain peptides or changes in their concentration may indicate, for instance, a change in the metabolic status. Pep-tides occur in blood as hormones, growth factors and cytokines, or degradation products of pro-teins.

BioVisioN has developed Peptidomics®-Technologies to analyse peptides and small molecules in a biological sample using a combination of peptide extraction and sample preparation, chromatogra-phy and mass spectrometry and bioinformatics. The existing approach of peptide analysis to ac-company clinical trials with large of sample sets to be analysed and each single sample containing thousands of possible biomarkers is very demanding. In the course of the project scientists of Bio-VisioN will improve Peptidomics-Technologies to allow for higher and faster throughput with even better sensitivity and reproducibility..

In addition, the grant includes the sequencing of the peptides in blood plasma. Dr. Peter Schulz-Knappe, Chief Scientific Officer of BioVisioN explains: 'The identification of the amino acid se-quence of peptide biomarkers is the key to the understanding of diseases or for the prediction of drug efficacy.'. The development of new sophisticated bioinformatic tools will further improve Bio-VisioN's capabilities in mapping, characterisation and comparison of peptide patterns.

In a further step BioVisioN will develop new methods for diagnostic applications, that will allow a fo-cused analysis of a single peptide biomarker in blood samples bringing the Peptidomics approach from R&D to routine clinical diagnostics.

'Today, BioVisioN has the chance to be the first company in the world to identify nearly all peptides in human blood plasma and set new standards for their analysis.', says Peter Schulz-Knappe about the future outlook for BioVisioN.

About BioProfile
The BioProfile 'Functional genome analysis' is an initiative of research facilities, universities and biotech companies from Lower Saxony. The initiative was one of three winners of the BioProfile competition organised by the German Federal Ministry of Education and Research. The participating institutions presented a successful joint concept for the development of biotechnology in the Braunschweig, Hannover, Göttingen 'triangle'. Up to EUR15 million project funds from the federal gov-ernment are now available in Lower Saxony on a pro-rata basis for projects in one of the three fo-cus-areas of the BioProfile.

About BioVisioN
BioVisioN AG specialises in the identification of disease-relevant peptides and proteins using Pep-tidomics and Differential Peptide Display. The company was founded in 1997 and today employs 45 people. Apart from research collaborations, BioVisioN provides access to its technology also in fee-for-service contracts as a Biological Research Organisation.

Publisher Contact Information:

BioVisioN AG

Company profile of BioVisioN AG (Acquired by Digilab)
Past press releases of BioVisioN AG (Acquired by Digilab).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.